Ikaria acquires peptide compounds from Fibrex
This article was originally published in Scrip
Executive Summary
Ikaria has acquired the global licence to Fibrex Medical's portfolio of investigational compounds, including the fibrin-derived peptides FX06, FX201 and FX107.